Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Stockholders' Equity (Unaudited)

v3.24.1.u1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Loss
Beginning balance, value at Dec. 31, 2022 $ 32,990,017 $ 417 $ 425,196,359 $ (392,080,667) $ (126,092)
Beginning balance, shares at Dec. 31, 2022   4,171,297      
Common stock shares issued   43,836      
Stock-based compensation expense 1,026,379   1,026,379    
Issuance of common stock upon exercise of stock options 129,745 $ 5 129,740    
Change in unrealized gain (loss) on marketable debt securities 57,623       57,623
Net Income (Loss) (17,744,812)     (17,744,812)  
Ending balance, value at Mar. 31, 2023 16,458,952 $ 422 426,352,478 (409,825,479) (68,469)
Ending balance, shares at Mar. 31, 2023   4,215,133      
Beginning balance, value at Dec. 31, 2023 (6,904,722) $ 442 429,780,375 (436,683,983) (1,556)
Beginning balance, shares at Dec. 31, 2023   4,423,683      
Issuance of common stock, net of issuance costs 108,762,524 $ 592 108,761,932    
Common stock shares issued   5,913,138      
Stock-based compensation expense 982,016   982,016    
Issuance of common stock upon exercise of stock options $ 226,603 $ 2 226,601    
Issuance of common stock upon exercise of stock options, shares 24,231 24,231      
Issuance of common stock upon vesting of restricted stock, shares   3,328      
Change in unrealized gain (loss) on marketable debt securities $ (326,949)       (326,949)
Issuance of common stock upon conversion of K2 Loan and Security Agreement, Shares   142,857      
Issuance of common stock upon conversion of K2 Loan and Security Agreement, Value 1,125,000 $ 14 1,124,986    
Net Income (Loss) (6,898,771)     (6,898,771)  
Ending balance, value at Mar. 31, 2024 $ 96,965,701 $ 1,050 $ 540,875,910 $ (443,582,754) $ (328,505)
Ending balance, shares at Mar. 31, 2024   10,507,237